Literature DB >> 29068853

Neonatal Rhizomelic Chondrodysplasia Punctata Type 1: Weaving Evidence Into Clinical Practice.

Jessica Landino1, Amy J Jnah, Desi M Newberry, Sabine C Iben.   

Abstract

Rhizomelic chondrodysplasia punctata (RCDP) is a rare genetic peroxisome biogenesis disorder with a reported incidence of 1 in 100 000 live births. The 3 genetic subtypes of RCDP are acquired by an autosomal recessive inheritance pattern. RCDP type 1 accounts for greater than 90% of all aggregate cases. Differentiating between the 3 subtypes of RCDP, as well as disorders characterized by similar punctate cartilaginous changes, is essential to guide an appropriate postnatal plan of care. Management strategies are focused toward associated clinical manifestations and require an interdisciplinary approach including ophthalmology, cardiovascular, endocrine, physical and occupational therapy, and neurology. Purposeful and frequent collaboration among all members of the neonatal/pediatric interdisciplinary team is necessary to optimize outcomes for the neonate and the family unit. The purpose of this article is to anticipate the needs of both patients with known and prenatal diagnosis of RCDP type 1 and patients with suspected clinical diagnosis of RCDP type 1 in the immediate neonatal period and to guide the appropriate plan of care. This article presents a case report of type I RCDP, as well as describes genetic influences, symptoms, diagnosis, management, and prognosis.

Entities:  

Mesh:

Year:  2017        PMID: 29068853     DOI: 10.1097/JPN.0000000000000282

Source DB:  PubMed          Journal:  J Perinat Neonatal Nurs        ISSN: 0893-2190            Impact factor:   1.638


  2 in total

1.  Rhizomelic chondrodysplasia punctata: Role of EEG as a biomarker of impending epilepsy.

Authors:  Debopam Samanta
Journal:  eNeurologicalSci       Date:  2019-12-04

2.  Peroxisomal Dysfunction in Neurological Diseases and Brain Aging.

Authors:  Ndidi-Ese Uzor; Louise D McCullough; Andrey S Tsvetkov
Journal:  Front Cell Neurosci       Date:  2020-03-10       Impact factor: 5.505

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.